Indonesia Compression Therapy Market Analysis

Indonesia Compression Therapy Market Executive Summary

Indonesia Compression Therapy Market was valued at $23 Mn in 2022 and is estimated to reach $35 Mn in 2030, exhibiting a CAGR of 5.6% during the forecast period.

Compression therapy, a medical procedure commonly used on limbs, aims to enhance blood circulation and reduce swelling. It is frequently employed for conditions like lymphedema, venous disorders, and specific edemas, with the primary goal of improving venous blood flow and preventing fluid buildup in tissues. Depending on the severity and individual needs, compression therapy may take various forms, such as elastic stockings, sleeves, or bandages. Techniques like compression wraps involve applying multiple layers for graduated compression, while intermittent pneumatic compression (IPC) mimics natural muscle contractions to aid venous return. Consulting with a healthcare provider is crucial to determine the most suitable technique and compression level, especially when developing comprehensive treatment plans for issues like poor circulation, swelling, or fluid retention.

In Indonesia, Chronic Venous Disease (CVD) presents a significant health concern, with a prevalence of approximately 26% for the C1 stage (visible varicose veins) and 8% for the C3 stage (skin changes and edema). Deep Vein Thrombosis (DVT) also poses a substantial risk, with a notably high incidence of 40.3%, suggesting a potentially higher prevalence compared to Western populations. Several factors contribute to the increased risk of these venous conditions in Indonesia. Rising obesity rates in the country may contribute to an elevated risk of CVD, while frequent childbearing, particularly common in certain regions, is identified as a risk factor for women. Lifestyle factors such as standing occupations, limited physical activity, and poor diet are likely contributors as well. Additionally, genetic predispositions within the Indonesian population could vary, further influencing susceptibility to venous conditions.

Compression therapy integration with telehealth platforms is a strategic approach toward improving patient convenience and access. Prominent corporations such as Bauerfeind and Juzo are actively participating in this endeavor, providing telehealth solutions that facilitate remote patient monitoring and assistance during compression therapy. This creative strategy offers a more individualized and patient-centred way to manage compression therapy, in line with the growing trend of digital health and adapting to changing patient needs.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Venous Disorders: A significantly elevated rate of 40.3% for deep vein thrombosis (DVT) and the potential rise in chronic venous disease (CVD) attributed to lifestyle elements such as obesity and reduced physical activity. The expanding number of affected individuals is fuelling the need for compression therapy interventions.

Rising Geriatric Population: In 2022, Indonesia's senior citizen population comprises almost 19 Mn individuals, making up 9.6% of the overall population. Projections from the United Nations suggest that this figure is set to increase significantly, reaching 25% by 2050. The surge in demand for compression therapy in Indonesia is primarily fuelled by the aging demographic. The country is confronting the challenges posed by a swiftly growing elderly population, leading to a higher prevalence of conditions such as lymphedema, varicose veins, and cardiovascular diseases.

Increasing Healthcare Awareness: The increasing awareness among healthcare professionals and the general public about the benefits of compression therapy is propelling the market's growth. The market is growing as a result of educational initiatives, professional and athlete support, and other factors.

Market Restraints

High Cost of Products: Expensive compression garments, particularly from international brands, can be costly. For a significant segment of the populace, especially those with limited disposable income or those who depend on public healthcare programs, this could be an obstacle to access.

Low Patient Compliance: Consistently wearing compression apparel throughout the day may cause discomfort and restrictions, diminishing adherence and effectiveness of the treatment. This is particularly evident in non-medical scenarios such as sports recovery or daily wear. Insufficient patient education and awareness regarding the lasting advantages of compression therapy also play a role in fostering low compliance.

Lack of Insurance Coverage: Comprehensive insurance options for compression therapy are not widely accessible in Indonesia, thereby restricting patients' ability to receive treatment, particularly for preventive or extended durations.

Healthcare Policies and Regulatory Landscape

The National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan, or BPOM) and the Ministry of Health (Kemenkes) collaborate closely to control the pharmaceutical treatment landscape in Indonesia. To guarantee the effectiveness, safety, and quality of pharmaceutical marketing authorizations, BPOM plays a crucial role in their approval and oversight. The Ministry of Health provides overarching guidelines for healthcare, shaping the standards adhered to by these medications. The availability and payment processes for medicines are greatly impacted by the national health insurance program, Jaminan Kesehatan Nasional (JKN). Ongoing efforts to establish health technology assessment mechanisms and enact laws governing clinical trials and research also impact the review and approval processes in this regulatory environment.

Competitive Landscape

Key Players

• Medtronic plc
• Sigvaris
• Bauerfeind
• Juzo
• McKesson Corporation
• Cardinal Health
• BSN Medical
• Hartmann
• Lohmann & Rauscher
• Molnlycke Health Care